Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
A6NEC2
UPID:
PSAL_HUMAN
Alternative names:
-
Alternative UPACC:
A6NEC2; A8MZ60
Background:
The Puromycin-sensitive aminopeptidase-like protein, identified by the accession number A6NEC2, plays a crucial role in the degradation of intracellular peptides. Its broad substrate specificity allows it to target and process various peptides, highlighting its importance in maintaining cellular homeostasis and protein turnover.
Therapeutic significance:
Understanding the role of Puromycin-sensitive aminopeptidase-like protein could open doors to potential therapeutic strategies. Its involvement in peptide processing suggests a pivotal role in cellular functions, which, when dysregulated, could lead to disease states. Targeting this protein could offer new avenues for intervention in diseases where peptide accumulation or misprocessing is a factor.